Stephen Hoge - 17 Mar 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: President
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 17 Mar 2022
Net transactions value: +$1,623,413
Form type: 4
Filing time: 21 Mar 2022, 18:07:02 UTC
Previous filing: 15 Mar 2022
Next filing: 25 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$2,917,945	+19,282	+1.2%	$151.33	1,630,073	17 Mar 2022	Direct	F1, F2
transaction	MRNA	Common Stock	Sale	$1,294,533	-7,541	-0.46%	$171.67	1,622,532	18 Mar 2022	Direct	F3
holding	MRNA	Common Stock						4,116	17 Mar 2022	By Valhalla, LLC
holding	MRNA	Common Stock						151,933	17 Mar 2022	By Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-19,282	-50%	$0.000000	19,283	17 Mar 2022	Common Stock	19,282	$0.000000	Direct	F1, F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the date of delivery of RSUs that were scheduled for vesting on February 28, 2022, but for which delivery was delayed until certain antitrust clearance requirements were obtained.
F2	Restricted stock units convert into common stock on a one-for-one basis.
F3	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4	These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5	50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.